MedTrace Logo

Dosing of Ketorolac Impacts Post-cesarean paiN manaGemenet (KING)

NCT05248984 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2026-02-25

Study results available
· View outcomes & findings →

Summary

This is a randomized controlled single blinded trial to compare the morphine milligram equivalents (MME) use in the first 24 hours postoperatively after cesarean section in patients receiving a single dose of 30 mg intravenous ketorolac vs. 60 mg intravenous ketorolac in the operating room after the end of surgery.

Conditions

  • Post Cesarean Pain

Interventions

DRUG

Ketorolac 30 Mg

Participants will receive single dose of intravenous (IV) Ketorolac 30mg

DRUG

Ketorolac 60 Mg

Participants will receive single dose of intravenous (IV) Ketorolac 60mg

Sponsors & Collaborators

  • Ohio State University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-08
Primary Completion
2023-11-30
Completion
2023-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05248984 on ClinicalTrials.gov